[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641035":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":30,"centralContacts":38,"locations":30,"responsibleParty":46,"collaborators":30,"id":50,"slug":30,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":30,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":30,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":71,"whyStopped":30,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":30},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"dexmedetomidine","EXPERIMENTAL","Dexmedetomidine 0.3mcg \u002Fkg over diluted in 10 ml 0.9% Na cl over 10 min and 10 min before end of surgery",[13],"Drug: Dexmedetomidine",{"label":15,"type":10,"description":16,"interventionNames":17},"Propofol plus lidocaine","Propofol 2mg\u002Fkg plus lidocaine 1mg\u002Fkg over 10 min and 10 min before end of surgery",[18],"Drug: Propofol",{"label":20,"type":21,"description":22,"interventionNames":23},"placebo","PLACEBO_COMPARATOR","receive placebo 10 ml 0.9% Nacl over 10 min and 10 min before end of surgery",[24],"Drug: Placebo",[26,31,35],{"type":27,"name":28,"description":11,"armGroupLabels":29,"otherNames":30},"DRUG","Dexmedetomidine",[9],null,{"type":27,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Propofol","Propofol 2mg\u002Fkg plus lidocaine 1mg\u002Fkg over 10 min and 10 min before end of surgery.",[15],{"type":27,"name":36,"description":22,"armGroupLabels":37,"otherNames":30},"Placebo",[20],[39,44],{"name":40,"role":41,"phone":42,"phoneExt":30,"email":43},"taher mohamed, residant","CONTACT","01120799228","taher2014mohamed@yahoo.com",{"name":45,"role":41,"phone":30,"phoneExt":30,"email":30},"elhadad ali mousa, professor",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Taher Mohamed Aboelyamin","Resident of Anesthesiology, Surgical ICU and Pain Medicine","100641035",false,"NCT07601698","Dexmedetomidine vs Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anasthesia","The Efficacy of Dexmedetomidine Versus Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anesthesia in Pediatric Ophthalmic Surgeries , A Prospective Randomized Comparative Controlled Study","Inclusion Criteria:\n\n* patients aged 2-8 years .\n* ASA physical status I-II.\n* Scheduled for elective surgeries under general anesthesia with sevoflurane\n\nExclusion Criteria:\n\n* History of psychiatric illness or cognitive impairment.\n* Known allergy to study drugs.\n* Severe cardiovascular, hepatic, or renal disease.\n* Chronic use of sedatives or opioids.",true,"ALL","2 Years","8 Years",{"count":61,"type":62},200,"ESTIMATED","INTERVENTIONAL",[65],"PHASE4","Primary we will Compare the Efficacy between Dexmedetomidine and \"Propofol-lidocaine\" mixture in preventing the post operative emergence agitation following sevoflurane anasthesia in pediatric ophthalmic surgeries Secondary we will evaluate time of extubation, time of orientation, Hemodynamic variables, Visual analog scale ( VAS), facial expressions scale , Adverse events",[68],"Emergence Agitation",[70],"EA","NOT_YET_RECRUITING","2026-05-19",{"date":74,"type":75},"2026-05-22","ACTUAL",{"date":77,"type":62},"2026-05-01",{"date":79,"type":62},"2026-12",{"name":5,"class":6}]